Sterile Compounding Pharmacies Market to Reach US$ 8.9 Billion by 2031

The global Sterile Compounding Pharmacies Market, valued at US$ 5.07 billion in 2020, is projected to grow at a robust compound annual growth rate (CAGR) of 7.2%, reaching US$ 8.9 billion by 2031. This comprehensive report from Fact.MR provides critical insights into market trends, technological advancements, and growth opportunities, offering actionable guidance for stakeholders in the pharmaceutical, healthcare, and medical technology sectors.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7061

What Are the Key Market Insights?

The sterile compounding pharmacies market is experiencing significant growth due to the rising demand for personalized medications tailored to individual patient needs, particularly for those with allergies, sensitivities, or requirements not met by commercially available drugs. Sterile compounding involves preparing customized medications, such as injectables, infusions, and ophthalmic solutions, in controlled environments to ensure safety and efficacy. Key growth drivers include the increasing prevalence of chronic diseases, such as cancer and cardiovascular disorders, which require specialized treatments like pain management and oncology injectables.

The aging global population, expected to reach 2.1 billion people aged 60 and older by 2050 according to the World Health Organization, is boosting demand for tailored formulations. Technological advancements, including robotic automation and automated compounding systems, enhance precision and safety, while regulatory frameworks like the Drug Quality and Security Act (DQSA) of 2013 ensure compliance and minimize safety risks. Challenges include contamination risks, high costs of maintaining sterile environments, and shortages of active pharmaceutical ingredients (APIs). Opportunities lie in the expansion of 503B outsourcing facilities and growing demand in regions like Asia-Pacific, driven by increasing healthcare investments.

What Are the Key Statistics and Forecasts?

The report provides precise data to inform strategic decision-making. In 2020, the global sterile compounding pharmacies market was valued at US$ 5.07 billion, with a historical CAGR of 5.8% from 2015 to 2020. It is projected to grow at a CAGR of 7.2% through 2031, reaching US$ 8.9 billion. The U.S. dominates with over 70% of the North American market share in 2021, driven by advanced healthcare infrastructure and high pharmaceutical spending.

The injectables segment, including sterile solutions and suspensions, accounts for 65% of the market share. North America holds the largest regional share, while Asia-Pacific is expected to be the fastest-growing region due to rising chronic disease prevalence and healthcare investments. The market is anticipated to expand 1.8 times its current valuation by 2031, reflecting strong growth potential.

How Can Industries Benefit from the Report?

Fact.MR's report offers tailored insights for various industries. Pharmaceutical companies and 503B outsourcing facilities can leverage the findings to develop high-quality, sterile compounded medications, addressing drug shortages and patient-specific needs in critical care settings. Hospitals and healthcare providers benefit from insights into outsourcing sterile compounding to ensure consistent, safe medication supplies for high patient volumes.

Manufacturers of compounding equipment can use the report to innovate automated systems, such as robotic compounding technologies, to meet stringent regulatory standards. The report also highlights opportunities in emerging markets and therapeutic areas like oncology and pain management, enabling stakeholders to optimize production, enhance compliance, and expand market presence. By analyzing regulatory trends and technological advancements, the report empowers businesses to drive innovation and capitalize on growth opportunities.

Browse Full Report: https://www.factmr.com/report/sterile-compounding-pharmacies-market

Who Published the Report, and Where Can It Be Accessed?

Fact.MR, a trusted market research firm serving 80% of Fortune 1,000 companies, authored this report. With over 600 domain experts and a database exceeding 100 million data points, Fact.MR employs a rigorous methodology combining qualitative and quantitative research, including stakeholder interviews, market surveys, and advanced analytics, to ensure accuracy and reliability.

Who Are the Key Players?

The sterile compounding pharmacies market is driven by leading companies focused on innovation and compliance. Prominent players include Fagron, PharMEDium Services LLC (AmerisourceBergen), Central Admixture Pharmacy Services, Inc., Wedgewood Pharmacy, and QuVa Pharma. These companies are investing in advanced compounding technologies, such as automated systems like COMECER S.p.A.'s Pharmoduct for sterile formulations, and pursuing strategic acquisitions to expand their footprint. For instance, in July 2022, Fagron acquired a 503B outsourcing facility in Boston from Fresenius Kabi to enhance its sterile compounding capabilities.

What Are the Recent Developments in the Market?

Recent advancements in the sterile compounding pharmacies market highlight a focus on technology and regulatory compliance. In May 2020, Central Admixture Pharmacy Services, Inc. launched three new sterile compounded suspensions, addressing patient-specific needs. In March 2023, Omnicell Inc. introduced the IVX Station, a robotic compounding technology that enhances safety through advanced vision systems and gravimetric verification in an ISO Class 5 environment. The National Association of Boards of Pharmacy (NABP) received FDA funding in October 2019 to develop a data-sharing system for improved oversight of sterile compounding pharmacies, reducing contamination risks.

The growing adoption of 503B outsourcing facilities, which produce large batches under current Good Manufacturing Practices (cGMP), is addressing hospital demand for ready-to-use sterile medications. These developments, coupled with innovations in aseptic techniques and automation, are shaping the market's future and enhancing patient safety.

Check out More Related Studies Published by Fact.MR:

Sterile Active Pharmaceutical Ingredient Market: https://www.factmr.com/report/1702/sterile-active-pharmaceutical-ingredient-market

Sterile Container Market: https://www.factmr.com/report/sterile-container-market

Sterile Injectable Drug Market: https://www.factmr.com/report/sterile-injectable-drug-market

Sterile Medical Packaging Market: https://www.factmr.com/report/sterile-medical-packaging-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.